Biodesix (NASDAQ:BDSX) Director Jack Schuler Buys 80,000 Shares of Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler purchased 80,000 shares of the company’s stock in a transaction that occurred on Friday, January 23rd. The shares were purchased at an average cost of $11.81 per share, for a total transaction of $944,800.00. Following the completion of the transaction, the director owned 1,543,210 shares in the company, valued at approximately $18,225,310.10. This represents a 5.47% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Biodesix Stock Up 9.8%

BDSX stock opened at $11.08 on Wednesday. The firm has a market cap of $88.15 million, a price-to-earnings ratio of -1.99 and a beta of 0.60. Biodesix, Inc. has a 1-year low of $3.44 and a 1-year high of $21.60. The firm has a fifty day moving average price of $7.75 and a two-hundred day moving average price of $7.73. The company has a debt-to-equity ratio of 41.11, a current ratio of 1.84 and a quick ratio of 1.84.

Biodesix (NASDAQ:BDSX) last posted its quarterly earnings results on Monday, November 3rd. The company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.60) by $0.44. Biodesix had a negative net margin of 49.31% and a negative return on equity of 504.41%. The company had revenue of $21.77 million for the quarter, compared to the consensus estimate of $20.98 million. Research analysts predict that Biodesix, Inc. will post -0.35 EPS for the current year.

Institutional Investors Weigh In On Biodesix

Hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd lifted its holdings in Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock worth $58,000 after purchasing an additional 102,494 shares during the period. Millennium Management LLC bought a new stake in shares of Biodesix during the 3rd quarter worth about $113,000. Oracle Investment Management Inc. acquired a new stake in shares of Biodesix in the 3rd quarter worth approximately $113,000. Finally, Aberdeen Group plc bought a new position in shares of Biodesix in the fourth quarter valued at approximately $1,784,000. 20.96% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on BDSX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Biodesix in a report on Monday, December 22nd. Wall Street Zen upgraded Biodesix from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $32.50.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.